Dual targeting of Nur77 and AMPKα by isoalantolactone inhibits adipogenesis in vitro and decreases body fat mass in vivo.

Yeon-Seop JungHyo-Seon LeeHye-Rin ChoKeuk-Jun KimJoung-Hee KimStephen H SafeSyng-Ook Lee

Published in: International journal of obesity (2005) (2018)

These results suggest that ISO dual targeting Nur77 and AMPKα during adipogenesis represents a novel class of mechanism-based antiadipogenic agents for treatment of obesity and associated metabolic disorders, including hyperlipidemia and fatty liver.

Keyphrases

high fat diet induced
insulin resistance
skeletal muscle
cancer therapy
metabolic syndrome
type diabetes
weight loss
protein kinase
weight gain
physical activity
replacement therapy